Showing 3961-3970 of 7016 results for "".
- Avacincaptad Pegol Shows Two-Year Benefit in Geographic Atrophyhttps://reachmd.com/news/avacincaptad-pegol-two-year-benefit-geographic-atrophy/2487040/Key Takeaways Avacincaptad pegol remained associated with less geographic atrophy growth than sham at 2 years, and both year-2 dosing schedules remained separated from sham. Study-eye choroidal neovascularization was reported in 11.6% of avacincaptad p
- Five-Year Outcomes of Aragonite Scaffold vs Standard Care for Knee Lesionshttps://reachmd.com/news/five-year-outcomes-of-aragonite-scaffold-vs-standard-care-for-knee-lesions/2486776/Key Takeaways Greater 5-year improvement in overall KOOS was observed with the aragonite-based implant than with standard surgical care. The implant group had a 74.7% overall KOOS responder rate versus 29.6% with standard surgical care, while treatment
- Avacincaptad Pegol Two-Year GATHER2 Results in Geographic Atrophyhttps://reachmd.com/news/avacincaptad-pegol-two-year-gather2-results-in-geographic-atrophy/2486781/Key Takeaways Both year-2 avacincaptad pegol dosing schedules were associated with less geographic atrophy growth than sham at 2 years. Patients receiving avacincaptad pegol were rerandomized at month 12 to monthly or every-other-month dosing, and both
- Repeated Sprint Training In Youth Athleteshttps://reachmd.com/news/repeated-sprint-training-in-youth-athletes/2486642/In youth athletes, repeated sprint training was associated with pooled gains in short sprint speed, change-of-direction performance, and best repeated-sprint ability, while several other measures were unchanged. This pattern came from a
- Allergan Aesthetics Launches Fourth Year of The Confidence Collectivehttps://reachmd.com/news/allergan-aesthetics-launches-fourth-year-of-the-confidence-collective/2486549/Allergan Aesthetics, an AbbVie company, has opened applications for the fourth year of The Confidence Collective, a BOTOX® Cosmetic-branded initiative focused on supporting women entrepreneurs, according to company-provided materials. The application window is open through April 29, 20
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://reachmd.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Review Links Youth Digital Media Use to Later Mental Health and Functional Riskshttps://reachmd.com/news/jama-pediatrics-review-links-youth-digital-media-use-to-later-mental-health-and-functional-risks/2486033/A longitudinal synthesis published in JAMA Pediatrics reports that heavier digital media engagement in youth has shown consistent associations with later mental h
- AAD 2026 Late-Breaking: RADIANT-AD One-Year Phase 3 Presentationhttps://reachmd.com/news/aad-2026-late-breaking-radiant-ad-one-year-phase-3-presentation/2486000/Connect Biopharma said in a GlobeNewswire press release that one-year Phase 3 results from Simcere’s atopic dermatitis program with
- Parent Stress Reduction and Early Childhood Obesity: Yale Trial Reporthttps://reachmd.com/news/parent-stress-reduction-childhood-obesity/2485985/A Yale randomized trial involved a parent-focused mindfulness and stress-management program integrate
- ECG screening in 14–35-Year-Olds: Yield, Interventions, and Repeat Checkshttps://reachmd.com/news/ecg-screening-in-1435-year-olds-yield-interventions-and-repeat-checks/2485833/A large ECG screening cohort of 14–35-year-olds is described in the CRY ECG screening cohort, with the report highlighting how often potentially serious conditions were detected, what